EUVIMEDEUVIMED entdecken
Crossref

Strategic prioritization of biobetter sub-technologies: A comparative analysis of marketability, productization, and intellectual property competitiveness

Tae-Kwon Kim, Jong-Ho Kim, Yong Kim, Seung-In Um, Gahee Lee

Journal of Intellectual Property Education and Research · 15.06.2026 · 14 (1) · 23-41

DOI: 10.12972/kosiper.2026.14.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Intellectual Property Education and Research, online erschienen am 15.06.2026. Verfasst von Tae-Kwon Kim und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biobetters are improved follow-on biologics that enhance the efficacy, safety, pharmacokinetic properties, or convenience of existing biologics and are distinct from biosimilars in terms of structural or functional innovation. This study examines eight biobetter sub-technologies—glycoengineering, PEGylation, Fc engineering, antibody fragments, antibody-drug conjugates, fusion proteins, bispecific antibodies, and bio prodrugs—to identify candidate areas in which Korea may have relative competitiveness. Three dimensions were compared: marketability, productization status, and intellectual property competitiveness. Marketability was assessed using market size and projected compound annual growth rate; productization status was evaluated using cumulative FDA approvals and approvals during the most recent five years; intellectual property competitiveness was examined using patent filings, recent filing growth, and supplementary qualitative indicators such as cites per patent and patent family size. The results show that bispecific antibodies exhibited the strongest signals in both marketability and productization. Antibody-drug conjugates also showed strong productization and qualitative patent signals. Fusion proteins showed relatively low marketability but high commercialization feasibility, whereas Fc engineering showed strong recent patent growth and expansion potential. Overall, bispecific antibodies, antibody-drug conjugates, fusion proteins, and Fc engineering are identified as the most promising candidate areas for Korea.

Zitieren

APA

Kim, T., Kim, J., Kim, Y., Um, S., & Lee, G. (2026). Strategic prioritization of biobetter sub-technologies: A comparative analysis of marketability, productization, and intellectual property competitiveness. Journal of Intellectual Property Education and Research, 14(1), 23-41. https://doi.org/10.12972/kosiper.2026.14.2

Vancouver

Kim T, Kim J, Kim Y, Um S, Lee G. Strategic prioritization of biobetter sub-technologies: A comparative analysis of marketability, productization, and intellectual property competitiveness. Journal of Intellectual Property Education and Research. 2026;14(1):23-41. doi:10.12972/kosiper.2026.14.2

BibTeX
@article{Kim2026,
  author = {Kim, Tae-Kwon and Kim, Jong-Ho and Kim, Yong and Um, Seung-In and Lee, Gahee},
  title = {Strategic prioritization of biobetter sub-technologies: A comparative analysis of marketability, productization, and intellectual property competitiveness},
  journal = {Journal of Intellectual Property Education and Research},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {23--41},
  doi = {10.12972/kosiper.2026.14.2}
}
Kostenlos starten →